OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer,

Slides:

Advertisements

Similar presentations

Regional Citrate Anticoagulation during CVVH in the

Advertisements

Effect of Timing of Initiation on Short-term Mortality in Critically Ill Children requiring CRRT Modini Vinai, MD Marita Thompson, MD Diane Gollhofer,

Norma J Maxvold Pediatric Critical Care

CRRT Continue Renal Replacement Therapy

Not necessarily a recipe

MANAGEMENT OF CONTINUOUS HEMODIALYSIS

The Center for Acute Care Nephrology The Blended Dialysis/PICU Program Jerry Schwartz, RN, BSN, MHHA Clinical Director, PICU Cincinnati Children’s Hospital.

Continuous Renal Replacement Therapy. Why continuous Therapies? Continuous therapies closely mimic the GFR of native kidneys Large amounts of fluid.

Advanced Adult Intravenous Calculations

ECMO in CRRT – What are the Data?

Intensive care conference: management of acid-base disorders with CRRT International Society of Nephrology 主講人 : R2 顏介立.

Access n If you don’t have it you might as well go home. n This is the most important aspect of CRRT therapy. n Adequacy. n Filter life. n Increased blood.

Pediatric Acute Renal Failure: CRRT/Dialysis Outcome Studies Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine.

Terminology and Common Issues in Pediatric CRRT John Gardner RN, BSN Nurse Manager Pediatric Nephrology & Transplant DeVos Children’s Hospital Grand Rapids.

Vascular Access for CRRT Timothy E Bunchman Professor & Director Helen DeVos Children’s Hospital Grand Rapids, MI (Thanks to Rick Hackbarth MD for his.

Pediatric CRRT: The Prescription

ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY Dawn M Eding RN BSN CCRN Pediatric Critical Care Helen DeVos Children's Hospital.

Hemodynamic changes during hemofiltration in meningococcal septicemia Dr Rajiv Chhabra Dr Prabhat Maheshwari Dr Claudine De Munter.

Pediatric CRRT: The Prescription Stuart L. Goldstein, MD Associate Professor of Pediatrics Baylor College of Medicine.

What form of anticoagulation is the “best” Or why is Citrate better then Heparin or Prostacyclin.

Practical Considerations for CRRT Helen Currier RN, BSN, CNN Nancy McAfee RN, BSN, CNN.

A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.

Anticoagulation in CRRT

Immunomodulation of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Renal Replacement Therapy Sasipha Tachaboon 1, Khajohn Tiranatanakul.

ANTICOAGULATION in CRRT: Heparin vs. Citrate

Tomáš Zaoral1, Michal Hladík1, Jana Zapletalová2 1Pediatric intensive care unit, Department of Pediatrics,Faculty of Medicine, University Hospital Ostrava.

DIALYSIS SOLUTIONS INC.

Common Prescription Errors in Pediatric CRRT: a “Top 10 List” Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital.

THE EFFECT OF TIMING OF INITITIATION OF CRRT ON PATIENTS REQUIRING EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) Asif Mansuri, MD, MRCPI Fellow, Division.

University of Pittsburgh

David Askenazi MD, MSPH Associate Professor of Pediatrics 2Smaller Circuits for Smaller Patients Improving Renal Support with Aquadex™ Machine.

Brophy University of Iowa Pediatric CRRT Anticoagulation Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital PCRRT.

Citrate Anticoagulation

Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.

REACTIVE OR PROACTIVE: WHICH IS BEST IN RENAL REPLACEMENT THERAPY PHOSPHATE CONTROL? Joanna Campion-Smith Gurudutta Venkatesha Molly McLaughlin Meeta Mallik.

Vascular Access Considerations and Options for Pediatric CRRT Stuart L. Goldstein, MD.

ANTICOAGULATION PCRRT 2008 Orlando Patrick Brophy MD Director Pediatric Nephrology University of Iowa- Children’s Hospital.

Complications of Pediatric CRRT Theresa A. Mottes RN Pediatric Dialysis/Research Nurse C.S. Mott Children’s Hospital University of Michigan.

Blunt Aortic Injury with Concomitant Intra-abdominal Solid Organ Injury: Treatment Priorities Revisited Santaniello J, et al, The Journal of TRAUMA Injury,

Carl P. Walther*, Amber S. Podoll*, Kevin W. Finkel* *The University of Texas Health Science Center at Houston Citrate Toxicity During CRRT After Massive.

PCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics.

Proposal of a flow-chart to avoid circuit clotting in prolonged intermittent renal replacement therapy (PIRRT): a monocentric experience 1 Vincenzo Cantaluppi,

Vascular Access in CRRT Timothy E Bunchman MD Professor & Director Pediatric Nephrology

Results Methods Abstract Number 69 Objectives 1.Nephrol Dial Transplant (2011) 26: 537–543 2.J Support Oncol 2011;9:149–155 3.N Engl J Med. 2009; 361:1627–1638.

Dosing of Anti-Fungal agents on CRRT Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children’s Hospital of Richmond.

Citrate Continuous Renal Replacement Therapy: Which Protocol? Standard Protocol 1 (SP1) Indication: First hours of therapy Effluent dose target:

CRRT TERMINOLOGY Stefano Picca, MD

CONTINUOUS RENAL REPLACEMENT THERAPY

CRRT Fundamentals Pre- and Post- Test

Including: Anticoagulation Prescribing Protocol

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

Access for Pediatric CRRT

Devices use for Neonatal AKI

Prescriptions in CRRT Timothy E Bunchman MD Professor & Director

CRRT Fundamentals Pre- and Post- Test Answers

Feeding Modality is a Barrier to Providing Adequate Protein to Pediatric Patients Receiving Continuous Renal Replacement Therapy Molly Wong Vega, MS, RDN.

Objectives Early initiation of continuous renal replacement therapy

T.Zaoral,M.Hladík, M.Sádlo, V.Vobruba

What are we trying to dialyse?

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.

Pediatric CRRT Terminology

Continuous renal replacement therapy in the critically ill patient

Access in Pediatric CRRT

Basics of CRRT: Terminology

J Foland, J Fortenberry, B Warshaw,

Children’s Memorial Hospital Northwestern University

CRRT dialysis circuit using regional citrate anticoagulation with the Gambro Prisma machine. CRRT dialysis circuit using regional citrate anticoagulation.

University of Alabama at Birmingham continuous venovenous hemodiafiltration (CVVHDF) protocol for 0.67 and 0.5% citrate. University of Alabama at Birmingham.

RCA in continuous RRT: basic principles

Presentation transcript:

OUTCOMES OF REGIONAL CITRATE ANTICOAGULATION (RCA) IN PEDIARTIC CONTINUOUS RENAL REPLACEMENT THERAPY (pCRRT) IN A SINGLE CENTER Issa Alhamoud, Diane Gollhofer, Raymond Quigley. Division of Pediatric Nephrology University of Texas Southwestern Medical Center, Children’s Medical Center, Dallas, Texas, United States I have no conflict of interests to resolve or disclose

Introduction: Objective: The efficacy of Continuous Renal Replacement Therapy (CRRT) in critically sick children is dependent largely on the anticoagulation of circuit. Systemic heparin. Regional citrate anticoagulation (RCA). Objective: Circuit lifetime with regional citrate anticoagulation versus systemic heparin. Circuit lifetime with RCA X1 (ml/hr) of blood flow rate (BFR) (ml/min) versus RCA X1.5 (ml/hr) of BFR (ml/min). Correlation between circuit ionized calcium and circuit lifetime.

Methods Retrospective study: Inclusion Criteria: All patients (1 day-21 years) who required CRRT>48 hours using either CVVH or CVVHDF including ECMO patients between Jan 2013-Dec 2016. Exclusion criteria: CRRT<48 hrs or CRRT without anticoagulation. Parameters: Circuit lifetime (hrs): RCA vs Heparin and RCA X1 of BFR vs RCA X1.5 of BFR. Mean circuit iCa for each circuit in citrate group. CRRT Protocol: BFR ACD-A CaCl 0.8% Heparin Dialysate Filter 2-12 ml/kg/min, rarely >150 ml/min 1.5X BFR (ml/hr) 1X BFR (ml/hr) Circuit iCa (0.3-0.6 mmol/l) 0.4X BFR (ml/hr) 0.3X BFR(ml/hr) Pt iCa(1.1-1.3 mmol/l Bolus: 10 units/kg Maintenance: 10-20 u/kg/hr ACTs(160-195) 2000 ml/1.73m²/hr. RCA: Ca-free HF1000 (1.1 m²)

Results Citrate Heparin P Patients number N=60 N=67 Age (Mon)(IQR) 126 (36-180) 60 (12-132) 0.004 Weight (kg)(IQR) 28 (17-57) 19(9.4-52) 0.011 Diagnosis Sepsis Malignancy/Sepsis BMT/Sepsis CHD Liver disease AKI/ESRD Drug ingestion Trauma 11 13 5 7 6 1 4 14 24 9 Mortality 23(38%) 28(41%) NS CRRT duration (hrs) 18670 12501 Filters number 337 258

Pt #:26 Circuits #: 149 T. duration: 8634 hrs Pt #:34 Circuits #: 188 T. duration: 10036 hrs

Conclusions Circuit lifetimes were longer in citrate-based anticoagulation as compared to systemic heparin. RCA that started at infusion rate (ml/hr) equal to BFR (Qb) (ml/min) had similar hemofitler lifespan to RCA that started at infusion rate 1.5 times of BFR. This could decrease the cost of CRRT and potentially reduce the risk of citrate toxicity. Circuit lifetime was negatively correlated with circuit ionized Calcium level